Contrarily to the Th-2-bias and eosinophil-dominated bronchial inflammation encountered in most asthmatics, other patients may exhibit neutrophil-predominant asthma sub-phenotypes along with Th-1 and Th-17 cells. However, the etiology of many neutrophil-dominated asthma subphenotypes remains ill-understood, in part due to a lack of appropriate experimental models. To better understand the distinct immune-pathological features of eosinophilic versus neutrophilic asthma types, we developed an Ovalbumin (OVA)-based mouse model of neutrophil-dominated allergic pulmonary inflammation. Consequently, we probed for particular inflammatory signatures and checkpoints underlying the immune-pathology in this new model as well as in a conventional, eosinophil-dominated asthma model. Briefly, mice were OVA-sensitized using either aluminium hydroxide (alum) or Complete Freund´s (CFA)-adjuvants followed by OVA aerosol challenge. T-cell, granulocyte and inflammatory mediator profiles were determined along with alveolar macrophage genome-wide transcriptome profiling. In contrast to the Th-2-dominated phenotype provoked by alum, OVA/CFA-adjuvant-based sensitization followed by allergen challenge elicited a pulmonary inflammation that was poorly controlled by dexamethasone, and in which Th-1 and Th-17 cells additionally participated. Analysis of the overall pulmonary and alveolar macrophage inflammatory mediator profiles revealed remarkable similarities between both models. Nevertheless, we observed pronounced differences in the IL-12/IFN-γ axis and its control by IL-18 and IL-18 Binding Protein (BP), but also in macrophage arachidonic acid metabolism and expression of T-cell instructive ligands. These differential signatures, superimposed onto a generic inflammatory signature, denote distinctive inflammatory checkpoints potentially involved in orchestrating neutrophil-dominated asthma.
Introduction
Predominance of eosinophils in the airway wall and sputum constitutes a major pathological hallmark of persistent mild-to-moderate asthma, commonly defined as a chronic inflammation of the airways mediated by Th-2 cells and provoked in atopic individuals by repeated cycles of allergen inhalation (5, 18, 25) . However, asthma is a heterogeneous disease and the emphasis on a Th-2-bias and eosinophilic bronchial inflammation fails to explain clinical observations in many cases in which patients present increased neutrophil cell counts in the airway lumen as a distinguishing trait, especially during acute exacerbations (13, 15, 21, 25) . Furthermore, Th-1 cells and cytotoxic T-cells (Tc), bronchiolitis and even alveolitis can often be detected in those patients (5, 9, 10, 18) . Recently obtained data also show involvement of Th-17 cells in the pathophysiology of neutrophil-predominant asthma, inducing the release of neutrophil-mobilizing cytokines from airway epithelial cells through IL-17 (1, 5, 9, 17, 28) . The etiology of neutrophiltype asthma forms is still ill-understood and precisely those patients with neutrophil-dominated inflammation often present with severe disease that appears resistant to conventional antiinflammatory glucocorticoid treatments (1, 12, 37) . Moreover, experimental research is hampered by the current lack of suitable mouse models that mimic specific features of this condition (14) .
Remarkably, several aspects of neutrophilic asthma are prominently found in another type of allergic airway disease, namely hypersensitivity pneumonitis (HP) (16, 33, 49) . Similarly to asthma, the HP-pathology is induced by exposure to airborne antigen in sensitized individuals.
Th-1, Th-17 and Tc-cells are the main lymphocytic components in HP and were shown to mediate pathology in experimental HP-models (20, 43) . Nevertheless, both allergic diseases differ in the nature of their causative agents: asthma-allergens are usually large proteins exerting enzymatic activity, whereas HP-eliciting allergens are often small proteins of microbial origin.
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Differences in Danger Associated Molecular Patterns (DAMPs), either intrinsic to the allergen or coinciding at the time of allergen inhalation, are considered as critical in determining the type of ensuing allergic disease (6) .
These considerations made us speculate that a neutrophil-dominated allergic airway inflammation reminiscent of common neutrophil-predominant asthma sub-phenotypes could be raised in vivo as the result of an 'accidental' Th-1/Th-17-biased sensitization against antigens that intrinsically do not elicit danger signals necessary to sustain this type of response (6) . In this study, we show that mice inhaling the model-allergen OVA develop allergic pulmonary inflammation with characteristics of neutrophil-predominant asthma if prior sensitization occurs in the presence of CFA, a potent Th-1/Th-17-skewing adjuvant commonly used in mouse models of HP (6, 20, 41, 43) . In addition, we exploited this new model of neutrophilic pulmonary inflammation as well as a conventional model of eosinophilic allergic pulmonary inflammation to seek by comparative expression analysis for distinct inflammatory signatures indicative of regulatory checkpoints controlling neutrophil-dominated asthma-like disease.
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Methods

Mouse models and collection of samples
In vitro restimulation of lung CD4 T-cells Page 9 of 34
Pooled lungs were minced and digested with collagenase. After removal of red blood cells, lung cells were seeded in culture medium + 1µg/ml anti-CD3. After 1h, Golgi-Plug (Pharmingen) was added and cells were cultured for another 4h upon which they were harvested for flowcytometric analysis as described above. Cells were first stained for surface markers (CD45, I-Ab, F4/80, CD4), then fixed and permeabilized, and subsequently stained for intracellular cytokines (IL-17,
IL-4, IFN-γ).
Measurement of inflammatory mediators in BAL fluid
Inflammatory mediators were measured in the first 0.5 mL fraction of the collected BAL fluid.
Cytokines and chemokines were measured using the Bioplex suspension array system (Biorad) according to the manufacturer's instructions, using recombinant cytokine standards (Biorad).
MMP-9 and MMP-12 levels were determined by SDS-PAGE western blot analysis, using specific monoclonal antibodies (R&D Systems) and peroxidase-conjugated rabbit-anti-mouse IgG (Dako, Denmark) for detection. Active MMP-9 was analyzed by zymography on a SDS-10% polyacrylamide gel + 1 mg/ml gelatin, detected as a lyses 95 kDa band. Culture medium from HT1080 cells served as internal standard. MMP-12 enzymatic activity was analyzed using the EnzoLyte 490 kit (AnaSpec, San Jose, CA, USA), optimized to detect MMP-12 activity in biological samples using a fluorescence quenched substrate (EDANS/DabcylPlusTM FRET peptide). MMP-12 purified enzyme used as positive control was purchased from Sigma (St Louis, Missouri, USA). Complement C3a levels were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA), using anti-C3a clone I87-1162 (BD Pharmingen) for capture and biotinylated I87-419 clone (BD Pharmingen) for detection. Purified mouse C3a protein (BD Pharmingen) was used as standard.
Page 10 of 34
RT-qPCR analysis
Total RNA was prepared using the Aurum total RNA mini kit (Biorad Hercules, CA). RNA quality was determined spectro-photometrically. For RT-qPCR, cDNA was prepared from 1 µg total RNA using oligo(dT), RNase inhibitor and SuperscriptII reverse transcriptase (all Invitrogen). PCR reactions were performed with the SybrGreen-I qPCR Core kit (Eurogentec, Liège, Belgium) and an iCycler (Biorad) instrument. Data were normalized for the expression levels of housekeeping genes (Ribosomal protein L13a and TATA box binding protein).
Amplification specificity was confirmed by evaluation of the melting curves. n-Fold differences between samples were calculated using the 2 -∆∆Ct method. The PCR primer pair sequences (Invitrogen) are provided in the Supplementary information.
Transcriptome analysis
RNA integrity was confirmed with the automated electrophoresis Experion System using the RNA StdSens Analysis Kit (Bio-Rad). 4 µg of total RNA, labeled using the GeneChip 
Results
Immunization with CFA predisposes mice to develop a neutrophilic asthma-like pulmonary inflammation that is poorly controlled by glucocorticoids
To verify to what extent Th-1/Th-17-biased sensitization supports the development of neutrophilic asthma-like inflammation, C57BL/6 mice were systemically immunized against the model antigen OVA in the presence of CFA. Sensitization promoting an eosinophilic asthma-like immunopathology was generated by immunization against OVA in the presence of the Th-2-skewing adjuvant alum. Thereafter, mice from both groups were challenged with nebulized OVA for two consecutive days. This then resulted in a significant cell infiltrate in the BAL fluid compared to naïve mice [ Fig.1A ]. and CD4 T-cells. In the OVA/CFA model however, 1mg/kg Dex had no effect on cellular inflammation while 2.5mg/kg Dex reduced the number of DC and CD4 T cells and to a lesser extent of eosinophils, but had no effect on the neutrophil cell count. Thus, using either alum or CFA as adjuvants predisposes mice to develop divergent types of pulmonary inflammation that are in line with many inflammatory aspects of respectively human eosinophilic and neutrophilic asthma types.
Lung CD4 T-cell phenotypes
We characterized the local Th-phenotype generated in the OVA/CFA-and OVA/alum-groups by performing RT-qPCR on magnetically purified lung tissue CD4 T-cells [ 
Innate inflammatory mediator signatures
We verified to what extent the differential T-cell polarization in OVA/CFA-versus OVA/alumconditions reflected at the local inflammatory mediator level. First, we performed RT-qPCR on total lung mRNA [ Fig.4A ]. Reflecting the cellular environment, mRNA expression of Th-1-chemoattractant (CXCL10) was induced solely in the OVA/CFA-condition, whereas the induction of Th-2-and eosinophil-recruiting chemokine (CCL11) was observed only in the OVA/alum-group. However, expression of two functionally similar chemokines, Th-1-chemoattractant CXCL9 and Th-2/eosinophil-recruiting CCL9, were induced in both conditions and only showed quantitative differences between both groups.
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Next, BAL fluid levels of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and chemokines (CXCL1/KC, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES) were analyzed by a multiplexed antibody assay [ Fig.4B ]. This revealed merely quantitative differences in inflammatory mediator expression between both groups. Of the cytokines and chemokines analyzed, only TNF-α was not induced, whereas the levels of IL-1β, IL-6 and monocyte/lymphocyte-attracting chemokines CCL2, CCL3, CCL4 and CCL5 were elevated in both groups. Surprisingly, also the levels of the neutrophil chemoattractant, CXCL1, were elevated in both groups to a similar extent. Yet, IL-1β, IL-6, CCL4 and CCL5 levels were more prominent in the OVA/CFA-mice.
Next to cytokines and chemokines, we also analyzed the expression levels of additional inflammatory mediators. The matrix metalloproteinases, MMP-9 and MMP-12, are thought to play detrimental roles in asthma. In line herewith, we observed increased levels of total or processed MMP-9 and MMP-12 levels in OVA/alum mice but also in the OVA/CFA model 
Generic and condition-specific immune effector gene signatures in AM
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The above clustering analysis of differentially expressed AM genes does not take into account quantitative differences in gene expression levels. Therefore, we selected for further analysis an immune effector gene set consisting of chemokines, cytokines, growth factors, genes involved in arachidonic acid metabolism, and genes involved in antigen processing and presentation. Genes having an expression pattern not more than 2-fold different between OVA/CFA and OVA/alum versus naïve were assigned to the generic signature. Genes showing 2-fold to 5-fold differences in expression between the respective inflammatory conditions versus naïve were assigned to the condition-biased signature. Finally, genes over 5-fold differentially expressed between the inflammatory models were assigned to the condition-specific signature. The expression levels of selected genes were further tested by RT-qPCR for confirmation in an independent repeat experiment. The results of this refined transcriptome analysis are shown in Figure 6 and discussed in the ensuing paragraphs.
Inflammatory mediator differentials
The majority of differentially expressed (versus naïve) chemo-and cytokines and growth factors showed mRNA levels that were identical or similar in OVA/CFA-and OVA/alum-conditions 
Discussion
In this study we addressed the issue of whether mouse models of neutrophil-dominated allergic pulmonary and bronchial inflammation could be developed suitable to effectively study the cellular and molecular pathways underlying such conditions. In humans, neutrophil-predominant asthma forms display some undeniable parallels with HP: neutrophilic infiltration, presence of Th-1, Th-17, and Tc cells, and alveolitis (1, 5, 10, 13-18, 21, 25, 28) . A classical protocol to predispose mice for HP consists of immunization against the actinomycete Saccharopolyspora rectivergula in the presence of CFA as Th-1/Th-17-inducing immunogenic co-factor (41).
Conversely, mice become predisposed to develop features of eosinophil-predominant asthma by systemic sensitization with OVA in the presence of the Th-2-skewing adjuvant alum (14) . We here combined these protocols by sensitizing mice against OVA in the presence of CFA.
Following OVA inhalation, the resulting pulmonary inflammation featured several cellular and In general, asthmatics with neutrophil-and Th-17-dominated inflammation tend to display an increased severity of disease, and both murine and clinical data suggest a relation with steroid resistance (1, 32, 42) . Indeed, we also found that, whereas Dex treatment dampened bronchoalveolar cellular infiltration as well as lung Th-2 numbers (not shown) in OVA/alum mice, little to no effect on bronchoalveolar infiltration or lung Th-1, Th-2, and Th-17 numbers was shown to have beneficial effects in mouse models (4, 7, 27) . Conversely, in AM from the neutrophil-dominated inflammation model, a shift towards chiefly prostanoid production is suggested by the increased expression of Ptgs2. COX2 (encoded by Ptgs2) has a higher affinity for arachidonic acid than COX1 (encoded by Ptgs1) (34) and preferentially synthesizes PGE 2 and PGI 2 (8) . The role of these two prostanoids in clinical asthma sub-phenotypes is elusive (26) , but in the allergically inflamed lung PGE 2 and PGI 2 are considered as anti-inflammatory agents (35, 46) . Thus, it appears that there exists a dichotomy in the AM arachidonic acid metabolism by which these cells attempt to control different types of inflammation. Clearly, more studies are required to confirm whether the differential Ptgs2 versus Ptgs1/Alox15 pathways in AM could be a discriminative feature of neutrophil versus eosinophil asthma types respectively. In conclusion, in this study we established a CFA-based mouse model mimicking the inflammatory and glucocorticoid-resistant component of neutrophil-predominant asthma.
Moreover, our results demonstrate the crucial role of immune potentiating factors present during allergic sensitization in determining the nature of the ensuing bronchial allergic response. Gating strategy is provided in Suppl. Fig. 2A . was considered significantly over-or underrepresented. 
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